Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
about
Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityFirst case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycinClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections.A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK.New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).High-dose daptomycin monotherapy cures Staphylococcus epidermidis 'endotipsitis' after failure of conventional therapy.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocarTolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study.Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay usiEfficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
P2860
Q33939055-30B1C83C-BD68-41D3-8FFD-AE8F6ED99DCEQ34116509-4291D3A7-771E-4D3D-A0E9-44ECDACDD137Q34157657-9C78ACD4-4B12-432B-8ABF-841FB240D74EQ34478074-C6E2900E-2C36-43CA-8EBE-D8CA51112DEDQ34573702-96F04532-1F56-40B4-9B36-1B4296CAC758Q35848781-35E926E5-D94C-4E65-8993-870C400DEC05Q36401160-5C88C7A9-FF8A-4BA5-A84F-94F0AF71BA8AQ36565462-57D0457C-840A-4E55-A1E1-9229FA138B51Q36969715-CD73ADF3-E544-44EE-A60D-15FD83007743Q37286911-DDF1C2B1-D52F-4250-85C0-D384E97A6C11Q37333049-18225668-4EB1-4483-80F3-31034E03341EQ38263421-034E3F64-18DB-4442-BF3B-1922AC6D3534Q39573063-595361C9-3BA6-4C2B-9205-141771A13304Q40018152-E54E538F-6E4B-406E-8A97-54BD3FF3A105Q40034329-8B8E586D-6235-4464-B063-12EEA9D574A0Q40360449-2489BB64-D237-44B7-A5D0-E0DAFFEB113CQ40441550-BF499653-22BE-4B42-9BAE-FDE3E7497BA8Q40631566-67FCC753-105E-4216-8D05-C08AECCB9440Q40845477-A950AB9D-FBB5-4A50-BF9A-0498684DB88FQ41570351-D3EC9A32-94F6-4A11-BA81-F37A94AA3516Q41755464-EFBEF9EB-63E1-4174-8CAE-1856F528A5B5Q41999444-AF0CE82C-E54C-4D9F-86EE-6255BAD5964DQ42003344-B1C5CE43-B871-43E7-888D-83D40DAEF305Q42008069-45B45524-19C6-4E41-8E5D-CDB48843A198Q42036509-DF8E7B8A-446E-43C3-9345-586BB9BEC24BQ42131112-658C9207-07B0-42C6-AEBA-3DD3F8468C1AQ42176732-0046E821-621A-4117-BF28-63A45ED910ECQ42363645-E1188A95-D527-4F3F-A6AC-6DA0B166ECEAQ42586714-1A4F6F9A-EE58-4EAF-B4B3-A7F05695A678Q42586811-41ECEB61-C271-457F-B800-2F955FFC9444Q42727129-7FD81CE8-3D0A-4B90-9A7A-F34D839A8EB3Q42789679-9E8F45F6-214F-41A4-A0F7-3820059294E3Q42854012-43550F0C-8CA9-4CCB-B05C-BABB0BD5D89BQ45936598-70348D72-F2D8-48B3-A12D-F0D5A323E0DAQ47318913-0EB0301D-B71A-4DEF-AC80-1ECCE32A403E
P2860
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@en
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@nl
type
label
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@en
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@nl
prefLabel
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@en
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@nl
P2093
P2860
P356
P1476
Evaluation of daptomycin pharm ...... lated endocardial vegetations.
@en
P2093
Michael J Rybak
Steven N Leonard
Warren E Rose
P2860
P304
P356
10.1128/AAC.00102-08
P407
P577
2008-06-30T00:00:00Z